Status:
ACTIVE_NOT_RECRUITING
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
Lead Sponsor:
Center for International Blood and Marrow Transplant Research
Collaborating Sponsors:
National Marrow Donor Program
Conditions:
Acute Myeloid Leukemia in Remission
Eligibility:
All Genders
18+ years
Brief Summary
Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoieti...
Detailed Description
This is a multi-center non-randomized prospective study designed to establish a national framework for introducing measurable residual disease testing into the clinical care of AML patients undergoing...
Eligibility Criteria
Inclusion
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Aged at least 18 years old at time of consent
- Diagnosed with AML, in complete remission
- Complete remission (CR) definition per local institutional criteria
- CR with incomplete hematologic recovery (CRi) is not an exclusion criterion
- MRD positivity is not an exclusion criterion
- Undergoing alloHCT
- Has a diagnostic AML specimen available
Exclusion
- Diagnosis of acute promyelocytic leukemia
- Prior alloHCT
Key Trial Info
Start Date :
August 26 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2029
Estimated Enrollment :
303 Patients enrolled
Trial Details
Trial ID
NCT05224661
Start Date
August 26 2022
End Date
July 1 2029
Last Update
April 25 2025
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
City of Hope
Duarte, California, United States, 91010
2
University of California, San Francisco
San Francisco, California, United States, 94143
3
Stanford University
Stanford, California, United States, 94305
4
University of Colorado
Aurora, Colorado, United States, 80045